Cost Variation Analysis Of Oral Antihypertensive Drugs Currently Available In Indian Pharmaceutical Market- A Pharmacoeconomic Study
DOI:
https://doi.org/10.37506/14d9s465Keywords:
Antihypertensive drugs,Pharmacoeconomic studies, Cost variation, Drug Prices Control OrderAbstract
BACKGROUND: Hypertension is one of the most commonly encountered chronic diseases, therefore treatment for the same should be affordable. Antihypertensive drugs of the same strength are available in the market at different costs. This study was conducted to raise awareness among health care workers and patients about the cost difference between different brands of the same antihypertensive drug, so that whenever possible a cheaper effective brand can be prescribed to ensure better patient adherence.
METHODS: Maximum retail price(MRP) of various antihypertensive drugs of same strength , manufactured by different pharmaceutical companies was obtained from various offline and online sources.The minimum and maximum costs of 10 tablets/capsules noted.The cost ratio & percentage cost variation was calculated for single drugs and fixed dose combinations.The ceiling price(as per DPCO)of common antihypertensives (as per national list of essential medicines)was compared with their maximum cost.
RESULTS: The formulations of single antihypertensive drugs and fixed drug combinations of two drugs were included in the study. Among the single antihypertensives analyzed the highest cost variation was of metoprolol (50mg) as high as 12144.89%.The cost ratio was seen to be seen to be highest for Metoprolol 50mg ER(80.3) followed by Metoprolol 25mg (78.4), Telmisartan 40mg(67).Among fixed dose combinations of two drugs analyzed highest cost variation was found that of Amlodipine 5mg + Atenolol 50mg combination(9566.6%)
CONCLUSIONS: There was a huge price variation among the antihypertensive drugs manufactured by various companies for the same strength.Some measures thus,must be taken by the government to bring the uniformity in the price that will help to reduce the economic burden on the patients.
References
Collins R, Peto R, MacMahon S, Godwin J, Qizilbash N, Hebert P, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease: part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet. 1990;335(8693):827-38.
Hansson L. The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens. 1996,14(5),537-44.
Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS medicine. 2007 Sep;4(9): e283.
Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. The National medical journal of India. 2004 Mar 1;17(2):80-3.
Firth J, Siddiqi N, Koyanagi AI, Siskind D, Rosenbaum S, Galletly C, Allan S, Caneo C, Carney R, Carvalho AF, Chatterton ML. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. The Lancet Psychiatry. 2019 Aug 1;6(8):675-712.
Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. British journal of clinical pharmacology. 1997 Apr;43(4):343
Devangi D, Shashirekha CH, Shruthi SL. Cost analysis study of different brands of commonly used drugs for bronchial asthma available in India -A Pharmacoeconomics study. Indian Journal of Pharmacy and Pharmacology. 2017;4(4):176-183.
Ray A, Najmi A, Khandelwal G, et al. A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders. Cureus. 2020; 12(5): e7964. DOI 10.7759/cureus.7964.
Jhanwar A. Pharmacoeconomic Analysis of Various Brands of Commonly Prescribed oral Anti hypertensive Medicines in Indian Market. Asian J Pharm Clin Res. 2022;15(3): 47-49.
http://janaushadhi.gov.in/SortingView.aspx
Karve A, Chattar K. Cost analysis study of oral antihypertensive agents available in Indian market. Int J Basic Clin Pharmacol.2014;3(3):479–83
Laxminarayana K, Satish GR. Cost variation analysis of antihypertensive drugs available in Indian market: An Economic Prospective. Int J Pharm Sci Res. 2016;7(5):2050–6
Limaye D. Cost-effectiveness study of Antihypertensive drugs in Mumbai, India. Int J Life Sci Pharma Res. 2018;8(1):97–103
Planning Commission Report. Government of India 2014. Available at: http://www.planningcommission.nic.in/reports/genre p/por_rep0707.pdf.
Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical Pricing Authority. Available at:https://www.nppaindia.nic.in/wpcontent/uploads/2020/03/1-1.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Monalisha Das, Hiteswar Saikia, Meghali Chaliha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en